Krognes named CFO of Denali Therapeutics
Steve Krognes is joining Denali Therapeutics Inc. as CFO effective Oct. 1. Krognes joins Denali from Genentech, where he has served as CFO and as a member of the Genentech Executive Committee since 2009. San Francisco-based Denali is a biotechnology company focused on developing therapies for neurodegenerative diseases. Investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund.
8 September 2015•3 mins read
